Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
13.14
-0.49 (-3.60%)
At close: May 12, 2025, 4:00 PM
13.04
-0.10 (-0.76%)
After-hours: May 12, 2025, 4:25 PM EDT
Benitec Biopharma Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Benitec Biopharma stock have an average target of 24.71, with a low estimate of 13 and a high estimate of 35. The average target predicts an increase of 88.05% from the current stock price of 13.14.
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 10, 2025.
Analyst Ratings
The average analyst rating for Benitec Biopharma stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Maintains $18 → $20 | Buy | Maintains | $18 → $20 | +52.21% | Apr 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +113.09% | Mar 24, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $18 | Buy | Reiterates | $18 | +36.99% | Mar 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +113.09% | Feb 21, 2025 |
| Baird | Baird | Buy Initiates $30 | Buy | Initiates | $30 | +128.31% | Dec 13, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.46
from -5.51
EPS Next Year
-2.13
from -1.46
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | n/a | n/a |
| Avg | n/a | n/a | n/a |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.10 | -1.25 | -0.49 |
| Avg | -1.46 | -2.13 | -1.96 |
| Low | -1.62 | -3.65 | -3.65 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.